Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
A metabolomic index based on lipoprotein subfractions and branched chain amino acids is associated with incident hypertension.

European journal of internal medicine

Flores-Guerrero JL, Connelly MA, Shalaurova I, Garcia E, Bakker SJL, Dullaart RPF.
PMID: 34321184
Eur J Intern Med. 2021 Dec;94:56-63. doi: 10.1016/j.ejim.2021.07.002. Epub 2021 Jul 25.

OBJECTIVE: The present study aims to evaluate the performance of the Diabetes Risk Index (DRI), a metabolomic index based on lipoprotein particles and branched chain amino acids, on the incidence of newly developed hypertension in a large community dwelling...

Cite
Flores-Guerrero JL, Connelly MA, Shalaurova I, et al. A metabolomic index based on lipoprotein subfractions and branched chain amino acids is associated with incident hypertension. Eur J Intern Med. 2021;94:56-63doi: 10.1016/j.ejim.2021.07.002.
Flores-Guerrero, J. L., Connelly, M. A., Shalaurova, I., Garcia, E., Bakker, S. J. L., & Dullaart, R. P. F. (2021). A metabolomic index based on lipoprotein subfractions and branched chain amino acids is associated with incident hypertension. European journal of internal medicine, 9456-63. https://doi.org/10.1016/j.ejim.2021.07.002
Flores-Guerrero, Jose L, et al. "A metabolomic index based on lipoprotein subfractions and branched chain amino acids is associated with incident hypertension." European journal of internal medicine vol. 94 (2021): 56-63. doi: https://doi.org/10.1016/j.ejim.2021.07.002
Flores-Guerrero JL, Connelly MA, Shalaurova I, Garcia E, Bakker SJL, Dullaart RPF. A metabolomic index based on lipoprotein subfractions and branched chain amino acids is associated with incident hypertension. Eur J Intern Med. 2021 Dec;94:56-63. doi: 10.1016/j.ejim.2021.07.002. Epub 2021 Jul 25. PMID: 34321184.
Copy Download .nbib Format: NLM
Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer.

Clinica chimica acta; international journal of clinical chemistry

Garcia E, Shalaurova I, Matyus SP, Wolak-Dinsmore J, Oskardmay DN, Connelly MA.
PMID: 34871562
Clin Chim Acta. 2021 Dec 04;524:106-112. doi: 10.1016/j.cca.2021.11.031. Epub 2021 Dec 04.

BACKGROUND: Choline, a gut microbiome metabolite, is associated with cardiovascular risk and other chronic illnesses. The aim was to develop a high-throughput nuclear magnetic resonance (NMR)-based assay to measure choline on the Vantera® Clinical Analyzer.METHODS: A non-negative deconvolution algorithm...

Cite
Garcia E, Shalaurova I, Matyus SP, et al. Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer. Clin Chim Acta. 2021;524:106-112doi: 10.1016/j.cca.2021.11.031.
Garcia, E., Shalaurova, I., Matyus, S. P., Wolak-Dinsmore, J., Oskardmay, D. N., & Connelly, M. A. (2021). Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer. Clinica chimica acta; international journal of clinical chemistry, 524106-112. https://doi.org/10.1016/j.cca.2021.11.031
Garcia, Erwin, et al. "Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer." Clinica chimica acta; international journal of clinical chemistry vol. 524 (2021): 106-112. doi: https://doi.org/10.1016/j.cca.2021.11.031
Garcia E, Shalaurova I, Matyus SP, Wolak-Dinsmore J, Oskardmay DN, Connelly MA. Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer. Clin Chim Acta. 2021 Dec 04;524:106-112. doi: 10.1016/j.cca.2021.11.031. Epub 2021 Dec 04. PMID: 34871562.
Copy Download .nbib Format: NLM
A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease.

Hepatology communications

Danford CJ, Connelly MA, Shalaurova I, Kim M, Herman MA, Nasser I, Otvos JD, Afdhal NH, Jiang ZG, Lai M.
PMID: 30556036
Hepatol Commun. 2018 Nov 01;2(12):1467-1478. doi: 10.1002/hep4.1267. eCollection 2018 Dec.

Nonalcoholic fatty liver disease (NAFLD) is a complex disease dictated by both genetic and environmental factors. While insulin resistance (IR) is a key pathogenic driver, two common genetic variants in patatin-like phospholipase domain containing 3 (

Cite
Danford CJ, Connelly MA, Shalaurova I, et al. A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018;2(12):1467-1478doi: 10.1002/hep4.1267.
Danford, C. J., Connelly, M. A., Shalaurova, I., Kim, M., Herman, M. A., Nasser, I., Otvos, J. D., Afdhal, N. H., Jiang, Z. G., & Lai, M. (2018). A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatology communications, 2(12), 1467-1478. https://doi.org/10.1002/hep4.1267
Danford, Christopher J, et al. "A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease." Hepatology communications vol. 2,12 (2018): 1467-1478. doi: https://doi.org/10.1002/hep4.1267
Danford CJ, Connelly MA, Shalaurova I, Kim M, Herman MA, Nasser I, Otvos JD, Afdhal NH, Jiang ZG, Lai M. A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018 Nov 01;2(12):1467-1478. doi: 10.1002/hep4.1267. eCollection 2018 Dec. PMID: 30556036; PMCID: PMC6287585.
Copy Download .nbib Format: NLM
Genome- and CD4+ T-cell methylome-wide association study of circulating trimethylamine-N-oxide in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN).

Journal of nutrition & intermediary metabolism

Aslibekyan S, Irvin MR, Hidalgo BA, Perry RT, Jeyarajah EJ, Garcia E, Shalaurova I, Hopkins PN, Province MA, Tiwari HK, Ordovas JM, Absher DM, Arnett DK.
PMID: 28439531
J Nutr Intermed Metab. 2017 Jun;8:1-7. doi: 10.1016/j.jnim.2017.03.002. Epub 2017 Mar 08.

BACKGROUND: Trimethylamine-N-oxide (TMAO), an atherogenic metabolite species, has emerged as a possible new risk factor for cardiovascular disease. Animal studies have shown that circulating TMAO levels are regulated by genetic and environmental factors. However, large-scale human studies have failed...

Cite
Aslibekyan S, Irvin MR, Hidalgo BA, et al. Genome- and CD4+ T-cell methylome-wide association study of circulating trimethylamine-N-oxide in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). J Nutr Intermed Metab. 2017;8:1-7doi: 10.1016/j.jnim.2017.03.002.
Aslibekyan, S., Irvin, M. R., Hidalgo, B. A., Perry, R. T., Jeyarajah, E. J., Garcia, E., Shalaurova, I., Hopkins, P. N., Province, M. A., Tiwari, H. K., Ordovas, J. M., Absher, D. M., & Arnett, D. K. (2017). Genome- and CD4+ T-cell methylome-wide association study of circulating trimethylamine-N-oxide in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). Journal of nutrition & intermediary metabolism, 81-7. https://doi.org/10.1016/j.jnim.2017.03.002
Aslibekyan, Stella, et al. "Genome- and CD4+ T-cell methylome-wide association study of circulating trimethylamine-N-oxide in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)." Journal of nutrition & intermediary metabolism vol. 8 (2017): 1-7. doi: https://doi.org/10.1016/j.jnim.2017.03.002
Aslibekyan S, Irvin MR, Hidalgo BA, Perry RT, Jeyarajah EJ, Garcia E, Shalaurova I, Hopkins PN, Province MA, Tiwari HK, Ordovas JM, Absher DM, Arnett DK. Genome- and CD4+ T-cell methylome-wide association study of circulating trimethylamine-N-oxide in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). J Nutr Intermed Metab. 2017 Jun;8:1-7. doi: 10.1016/j.jnim.2017.03.002. Epub 2017 Mar 08. PMID: 28439531; PMCID: PMC5400362.
Copy Download .nbib Format: NLM
Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index.

Journal of clinical medicine

Garcia E, Shalaurova I, Matyus SP, Oskardmay DN, Otvos JD, Dullaart RPF, Connelly MA.
PMID: 31979327
J Clin Med. 2020 Jan 23;9(2). doi: 10.3390/jcm9020321.

BACKGROUND: Quantifying mildly elevated ketone bodies is clinically and pathophysiologically relevant, especially in the context of disease states as well as for monitoring of various diets and exercise regimens. As an alternative assay for measuring ketone bodies in the...

Cite
Garcia E, Shalaurova I, Matyus SP, et al. Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index. J Clin Med. 2020;9(2)doi: 10.3390/jcm9020321.
Garcia, E., Shalaurova, I., Matyus, S. P., Oskardmay, D. N., Otvos, J. D., Dullaart, R. P. F., & Connelly, M. A. (2020). Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index. Journal of clinical medicine, 9(2), . https://doi.org/10.3390/jcm9020321
Garcia, Erwin, et al. "Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index." Journal of clinical medicine vol. 9,2 (2020). doi: https://doi.org/10.3390/jcm9020321
Garcia E, Shalaurova I, Matyus SP, Oskardmay DN, Otvos JD, Dullaart RPF, Connelly MA. Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index. J Clin Med. 2020 Jan 23;9(2). doi: 10.3390/jcm9020321. PMID: 31979327; PMCID: PMC7074331.
Copy Download .nbib Format: NLM
Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial.

EClinicalMedicine

Huffman KM, Parker DC, Bhapkar M, Racette SB, Martin CK, Redman LM, Das SK, Connelly MA, Pieper CF, Orenduff M, Ross LM, Ramaker ME, Dorling JL, Rosen CJ, Shalaurova I, Otvos JD, Kraus VB, Kraus WE.
PMID: 35028547
EClinicalMedicine. 2022 Jan 03;43:101261. doi: 10.1016/j.eclinm.2021.101261. eCollection 2022 Jan.

BACKGROUND: For many cardiovascular risk factors there is no lower limit to which further reduction will result in decreased disease risk; this includes values within ranges considered normal for healthy adults. This seems to be true for new emerging...

Cite
Huffman KM, Parker DC, Bhapkar M, et al. Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial. EClinicalMedicine. 2022;43:101261doi: 10.1016/j.eclinm.2021.101261.
Huffman, K. M., Parker, D. C., Bhapkar, M., Racette, S. B., Martin, C. K., Redman, L. M., Das, S. K., Connelly, M. A., Pieper, C. F., Orenduff, M., Ross, L. M., Ramaker, M. E., Dorling, J. L., Rosen, C. J., Shalaurova, I., Otvos, J. D., Kraus, V. B., Kraus, W. E. (2022). Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial. EClinicalMedicine, 43101261. https://doi.org/10.1016/j.eclinm.2021.101261
Huffman, Kim M, et al. "Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial." EClinicalMedicine vol. 43 (2022): 101261. doi: https://doi.org/10.1016/j.eclinm.2021.101261
Huffman KM, Parker DC, Bhapkar M, Racette SB, Martin CK, Redman LM, Das SK, Connelly MA, Pieper CF, Orenduff M, Ross LM, Ramaker ME, Dorling JL, Rosen CJ, Shalaurova I, Otvos JD, Kraus VB, Kraus WE. Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial. EClinicalMedicine. 2022 Jan 03;43:101261. doi: 10.1016/j.eclinm.2021.101261. eCollection 2022 Jan. PMID: 35028547; PMCID: PMC8741476.
Copy Download .nbib Format: NLM
Effects of Amount, Intensity, and Mode of Exercise Training on Insulin Resistance and Type 2 Diabetes Risk in the STRRIDE Randomized Trials.

Frontiers in physiology

Ross LM, Slentz CA, Zidek AM, Huffman KM, Shalaurova I, Otvos JD, Connelly MA, Kraus VB, Bales CW, Houmard JA, Kraus WE.
PMID: 33613319
Front Physiol. 2021 Feb 04;12:626142. doi: 10.3389/fphys.2021.626142. eCollection 2021.

BACKGROUND: Lipoprotein Insulin Resistance Index (LP-IR) and Diabetes Risk Index are novel spectroscopic multimarkers of insulin resistance and type 2 diabetes risk. As the Studies of a Targeted Risk Reduction Intervention through Defined Exercise (STRRIDE) randomized trials have previously...

Cite
Ross LM, Slentz CA, Zidek AM, et al. Effects of Amount, Intensity, and Mode of Exercise Training on Insulin Resistance and Type 2 Diabetes Risk in the STRRIDE Randomized Trials. Front Physiol. 2021;12:626142doi: 10.3389/fphys.2021.626142.
Ross, L. M., Slentz, C. A., Zidek, A. M., Huffman, K. M., Shalaurova, I., Otvos, J. D., Connelly, M. A., Kraus, V. B., Bales, C. W., Houmard, J. A., & Kraus, W. E. (2021). Effects of Amount, Intensity, and Mode of Exercise Training on Insulin Resistance and Type 2 Diabetes Risk in the STRRIDE Randomized Trials. Frontiers in physiology, 12626142. https://doi.org/10.3389/fphys.2021.626142
Ross, Leanna M, et al. "Effects of Amount, Intensity, and Mode of Exercise Training on Insulin Resistance and Type 2 Diabetes Risk in the STRRIDE Randomized Trials." Frontiers in physiology vol. 12 (2021): 626142. doi: https://doi.org/10.3389/fphys.2021.626142
Ross LM, Slentz CA, Zidek AM, Huffman KM, Shalaurova I, Otvos JD, Connelly MA, Kraus VB, Bales CW, Houmard JA, Kraus WE. Effects of Amount, Intensity, and Mode of Exercise Training on Insulin Resistance and Type 2 Diabetes Risk in the STRRIDE Randomized Trials. Front Physiol. 2021 Feb 04;12:626142. doi: 10.3389/fphys.2021.626142. eCollection 2021. PMID: 33613319; PMCID: PMC7892901.
Copy Download .nbib Format: NLM
Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer.

Clinica chimica acta; international journal of clinical chemistry

Garcia E, Shalaurova I, Matyus SP, Wolak-Dinsmore J, Oskardmay DN, Connelly MA.
PMID: 34871562
Clin Chim Acta. 2021 Dec 04;524:106-112. doi: 10.1016/j.cca.2021.11.031. Epub 2021 Dec 04.

BACKGROUND: Choline, a gut microbiome metabolite, is associated with cardiovascular risk and other chronic illnesses. The aim was to develop a high-throughput nuclear magnetic resonance (NMR)-based assay to measure choline on the Vantera® Clinical Analyzer.METHODS: A non-negative deconvolution algorithm...

Cite
Garcia E, Shalaurova I, Matyus SP, et al. Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer. Clin Chim Acta. 2021;524:106-112doi: 10.1016/j.cca.2021.11.031.
Garcia, E., Shalaurova, I., Matyus, S. P., Wolak-Dinsmore, J., Oskardmay, D. N., & Connelly, M. A. (2021). Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer. Clinica chimica acta; international journal of clinical chemistry, 524106-112. https://doi.org/10.1016/j.cca.2021.11.031
Garcia, Erwin, et al. "Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer." Clinica chimica acta; international journal of clinical chemistry vol. 524 (2021): 106-112. doi: https://doi.org/10.1016/j.cca.2021.11.031
Garcia E, Shalaurova I, Matyus SP, Wolak-Dinsmore J, Oskardmay DN, Connelly MA. Quantification of choline in serum and plasma using a clinical nuclear magnetic resonance analyzer. Clin Chim Acta. 2021 Dec 04;524:106-112. doi: 10.1016/j.cca.2021.11.031. Epub 2021 Dec 04. PMID: 34871562.
Copy Download .nbib Format: NLM
Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.

Journal of clinical medicine

Bedi S, Garcia E, Jeyarajah EJ, Shalaurova I, Perez-Matos MC, Jiang ZG, Dullaart RPF, Matyus SP, Kirk WJ, Otvos JD, Davidson WS, Connelly MA.
PMID: 32927635
J Clin Med. 2020 Sep 10;9(9). doi: 10.3390/jcm9092915.

BACKGROUND: Lipoprotein particles with abnormal compositions, such as lipoprotein X (LP-X) and lipoprotein Z (LP-Z), have been described in cases of obstructive jaundice and cholestasis. The study objectives were to: (1) develop an NMR-based assay for quantification of plasma/serum...

Cite
Bedi S, Garcia E, Jeyarajah EJ, et al. Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay. J Clin Med. 2020;9(9)doi: 10.3390/jcm9092915.
Bedi, S., Garcia, E., Jeyarajah, E. J., Shalaurova, I., Perez-Matos, M. C., Jiang, Z. G., Dullaart, R. P. F., Matyus, S. P., Kirk, W. J., Otvos, J. D., Davidson, W. S., & Connelly, M. A. (2020). Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay. Journal of clinical medicine, 9(9), . https://doi.org/10.3390/jcm9092915
Bedi, Shimpi, et al. "Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay." Journal of clinical medicine vol. 9,9 (2020). doi: https://doi.org/10.3390/jcm9092915
Bedi S, Garcia E, Jeyarajah EJ, Shalaurova I, Perez-Matos MC, Jiang ZG, Dullaart RPF, Matyus SP, Kirk WJ, Otvos JD, Davidson WS, Connelly MA. Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay. J Clin Med. 2020 Sep 10;9(9). doi: 10.3390/jcm9092915. PMID: 32927635; PMCID: PMC7564541.
Copy Download .nbib Format: NLM
Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial.

EClinicalMedicine

Huffman KM, Parker DC, Bhapkar M, Racette SB, Martin CK, Redman LM, Das SK, Connelly MA, Pieper CF, Orenduff M, Ross LM, Ramaker ME, Dorling JL, Rosen CJ, Shalaurova I, Otvos JD, Kraus VB, Kraus WE.
PMID: 35028547
EClinicalMedicine. 2022 Jan 03;43:101261. doi: 10.1016/j.eclinm.2021.101261. eCollection 2022 Jan.

BACKGROUND: For many cardiovascular risk factors there is no lower limit to which further reduction will result in decreased disease risk; this includes values within ranges considered normal for healthy adults. This seems to be true for new emerging...

Cite
Huffman KM, Parker DC, Bhapkar M, et al. Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial. EClinicalMedicine. 2022;43:101261doi: 10.1016/j.eclinm.2021.101261.
Huffman, K. M., Parker, D. C., Bhapkar, M., Racette, S. B., Martin, C. K., Redman, L. M., Das, S. K., Connelly, M. A., Pieper, C. F., Orenduff, M., Ross, L. M., Ramaker, M. E., Dorling, J. L., Rosen, C. J., Shalaurova, I., Otvos, J. D., Kraus, V. B., Kraus, W. E. (2022). Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial. EClinicalMedicine, 43101261. https://doi.org/10.1016/j.eclinm.2021.101261
Huffman, Kim M, et al. "Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial." EClinicalMedicine vol. 43 (2022): 101261. doi: https://doi.org/10.1016/j.eclinm.2021.101261
Huffman KM, Parker DC, Bhapkar M, Racette SB, Martin CK, Redman LM, Das SK, Connelly MA, Pieper CF, Orenduff M, Ross LM, Ramaker ME, Dorling JL, Rosen CJ, Shalaurova I, Otvos JD, Kraus VB, Kraus WE. Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial. EClinicalMedicine. 2022 Jan 03;43:101261. doi: 10.1016/j.eclinm.2021.101261. eCollection 2022 Jan. PMID: 35028547; PMCID: PMC8741476.
Copy Download .nbib Format: NLM
A Newly Developed Diabetes Risk Index, Based on Lipoprotein Subfractions and Branched Chain Amino Acids, is Associated with Incident Type 2 Diabetes Mellitus in the PREVEND Cohort.

Journal of clinical medicine

Flores-Guerrero JL, Gruppen EG, Connelly MA, Shalaurova I, Otvos JD, Garcia E, Bakker SJL, Dullaart RPF.
PMID: 32867285
J Clin Med. 2020 Aug 27;9(9). doi: 10.3390/jcm9092781.

OBJECTIVE: Evaluate the ability of a newly developed diabetes risk score, the Diabetes Risk Index (DRI), to predict incident type 2 diabetes mellitus (T2D) in a large adult population.METHODS: The DRI was developed by combining the Lipoprotein Insulin Resistance...

Cite
Flores-Guerrero JL, Gruppen EG, Connelly MA, et al. A Newly Developed Diabetes Risk Index, Based on Lipoprotein Subfractions and Branched Chain Amino Acids, is Associated with Incident Type 2 Diabetes Mellitus in the PREVEND Cohort. J Clin Med. 2020;9(9)doi: 10.3390/jcm9092781.
Flores-Guerrero, J. L., Gruppen, E. G., Connelly, M. A., Shalaurova, I., Otvos, J. D., Garcia, E., Bakker, S. J. L., & Dullaart, R. P. F. (2020). A Newly Developed Diabetes Risk Index, Based on Lipoprotein Subfractions and Branched Chain Amino Acids, is Associated with Incident Type 2 Diabetes Mellitus in the PREVEND Cohort. Journal of clinical medicine, 9(9), . https://doi.org/10.3390/jcm9092781
Flores-Guerrero, Jose L, et al. "A Newly Developed Diabetes Risk Index, Based on Lipoprotein Subfractions and Branched Chain Amino Acids, is Associated with Incident Type 2 Diabetes Mellitus in the PREVEND Cohort." Journal of clinical medicine vol. 9,9 (2020). doi: https://doi.org/10.3390/jcm9092781
Flores-Guerrero JL, Gruppen EG, Connelly MA, Shalaurova I, Otvos JD, Garcia E, Bakker SJL, Dullaart RPF. A Newly Developed Diabetes Risk Index, Based on Lipoprotein Subfractions and Branched Chain Amino Acids, is Associated with Incident Type 2 Diabetes Mellitus in the PREVEND Cohort. J Clin Med. 2020 Aug 27;9(9). doi: 10.3390/jcm9092781. PMID: 32867285; PMCID: PMC7563197.
Copy Download .nbib Format: NLM
Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis.

Hepatology (Baltimore, Md.)

Hu K, Perez-Matos MC, Argemi J, Vilar-Gomez E, Shalaurova I, Bullitt E, Landeen L, Sugahara G, Deng H, Mathur K, Tran S, Cai H, He H, Yalcin Y, Vieira Barbosa J, Ventura-Cots M, Marx K, Gad AP, Niezen S, Izunza Barba S, Ang LH, Popov YV, Fricker Z, Lai M, Curry M, Afdhal N, Szabo G, Mukamal KJ, Sanyal AJ, Otvos JD, Malik R, Saito T, Connelly MA, Chalasani NP, Bataller R, Jiang ZG.
PMID: 34662439
Hepatology. 2021 Oct 18; doi: 10.1002/hep.32203. Epub 2021 Oct 18.

BACKGROUND AND AIMS: Lipoprotein Z (LP-Z) is an abnormal free cholesterol (FC)-enriched LDL-like particle discovered from patients with cholestatic liver disease. This study aims to define the diagnostic value of LP-Z in alcohol-associated hepatitis (AH) and interrogate the biology...

Cite
Hu K, Perez-Matos MC, Argemi J, et al. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology. 2021;doi: 10.1002/hep.32203.
Hu, K., Perez-Matos, M. C., Argemi, J., Vilar-Gomez, E., Shalaurova, I., Bullitt, E., Landeen, L., Sugahara, G., Deng, H., Mathur, K., Tran, S., Cai, H., He, H., Yalcin, Y., Vieira Barbosa, J., Ventura-Cots, M., Marx, K., Gad, A. P., Niezen, S., Izunza Barba, S., Ang, L. H., Popov, Y. V., Fricker, Z., Lai, M., Curry, M., Afdhal, N., Szabo, G., Mukamal, K. J., Sanyal, A. J., Otvos, J. D., Malik, R., Saito, T., Connelly, M. A., Chalasani, N. P., Bataller, R., & Jiang, Z. G. (2021). Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32203
Hu, Kunpeng, et al. "Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32203
Hu K, Perez-Matos MC, Argemi J, Vilar-Gomez E, Shalaurova I, Bullitt E, Landeen L, Sugahara G, Deng H, Mathur K, Tran S, Cai H, He H, Yalcin Y, Vieira Barbosa J, Ventura-Cots M, Marx K, Gad AP, Niezen S, Izunza Barba S, Ang LH, Popov YV, Fricker Z, Lai M, Curry M, Afdhal N, Szabo G, Mukamal KJ, Sanyal AJ, Otvos JD, Malik R, Saito T, Connelly MA, Chalasani NP, Bataller R, Jiang ZG. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology. 2021 Oct 18; doi: 10.1002/hep.32203. Epub 2021 Oct 18. PMID: 34662439.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries